Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02158507 · ClinicalTrials.gov registry record · NA
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02158507 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT02158507, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness and safety of the combination of two drugs, Veliparib and Lapatinib, given to participants with metastatic triple negative breast cancer that have undergone previous treatment. Veliparib is an investigational drug and has not been approved by the FDA while Lapatinib has been approved by the FDA for another type of breast cancer. All eligible participants will receive the study medications and not a placebo.
Interventions
- DRUG Combination of Veliparib + Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-09-04 |
| Est. Completion | 2021-07-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02158507
The ClinicalTrials.gov registry entry for NCT02158507 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combination of Veliparib + Lapatinib is the first listed.
NCT02158507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02158507 about?
NCT02158507 is a clinical study titled "Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer". This study will evaluate the effectiveness and safety of the combination of two drugs, Veliparib and Lapatinib, given to participants with metastatic triple negative breast cancer that have undergone previous treatment. Veliparib is an investigational drug and has not been approved by the FDA while ...
What is the current status of trial NCT02158507?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-09-04. Estimated completion is 2021-07-22.
What interventions are being tested in trial NCT02158507?
The interventions under investigation include: Combination of Veliparib + Lapatinib (DRUG).
Who is sponsoring clinical trial NCT02158507?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.